Synthetic Biologics Inc. Shares Close the Week 25.2% Higher - Weekly Wrap
The company saw its shares close the week 25.2% higher than last week, with trading volume higher than its 30 day average.
Jun 11, 2021 by Kwhen Finance Editors
Synthetic Biologics Inc. (SYN) shares closed this week 25.2% higher than it did at the end of last week. The stock is currently up 88.0% year-to-date, up 61.0% over the past 12 months, and down 98.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 1.2%.
Trading Activity
- Shares traded as high as $0.72 and as low as $0.56 this week.
- Shares closed 6e+1% below its 52-week high and 1e+2% above its 52-week low.
- Trading volume this week was 78.8% higher than the 10-day average and 191.0% higher than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
- The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Synthetic Biologics Inc. | -9.7 | 88.0 | 61.0 | -59.1 | 166.3 |
| Dow Jones Industrial Average | 0.0 | 13.6 | 30.1 | -1.3 | 41.6 |
| S&P 500 Index | 0.2 | 13.7 | 34.9 | -0.1 | 45.2 |
| Health Care | 1.5 | 10.7 | 24.5 | -0.3 | 33.3 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by 351.5%
- The company's stock price performance over the past 12 months beats the peer average by 334.8%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Synthetic Biologics Inc. | SYN | 0 | 88.0 | 61.0 | -59.1 | 166.3 |
| Peer Avg | N/A | 23.1 | 19.5 | 14.0 | -7.1 | 17.8 |
| Pfizer Inc. | PFE | 20.5 | 12.8 | 17.9 | -3.7 | 33.9 |
| Abbott Laboratories | ABT | 34.2 | 1.4 | 21.3 | -13.9 | 30.0 |
| Merck & Co Inc | MRK | 27.4 | -6.1 | -3.9 | -10.7 | 7.7 |
| Astrazeneca plc - ADR | AZN | 38.8 | 20.0 | 12.7 | ||
| Biogen Inc | BIIB | 20.7 | 69.4 | 40.5 | ||
| Teva- Pharmaceutical Industries Ltd. - ADR | TEVA | -3.2 | 19.5 | -4.3 | -14.3 | 35.1 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: